Here’s an interesting trial that explored the use of fluciclovine PET/CT for differentiating recurrent brain metastasis from radionecrosis. Patients (n=23) with equivocal lesions on MRI who were having a planned resection underwent fluciclovine PET. They found that criteria of SUVmax 4.8 or higher or activity visually greater than the parotid gland had an 80% sensitivity, ~80% specificity, ~75% PPV, and ~84% NPV for recurrent disease. | Kotecha, ASCO 2023
